TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07858916: A Phase 2b, Randomized, Controlled, Open-label Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) Profiles of TNP-2092 Administered Via Intra-articular (IA) Injection on a Background of Antibiotic

Sponsor: TenNor Therapeutics (Zhongshan) Limited · Phase: PHASE2 · Area: INFECTIOUS_VACCINE · Target Enrollment: 40 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$7,232,400

Rescue Site Savings

+$4,762,800

Unlock Full NCT07858916 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07858916 Rescue Dossier →